Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.

@article{Paul2018ColistinAV,
  title={Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.},
  author={Mical Paul and Georgios L. Daikos and Emanuele Durante-Mangoni and Dafna Yahav and Yehuda Carmeli and Yael Dishon Benattar and Anna Skiada and Roberto Andini and Noa Eliakim-Raz and Amir Nutman and Oren Zusman and Anastasia Antoniadou and Pia Clara Pafundi and Amos Adler and Yaakov Dickstein and Ioannis Pavleas and Rosa Zampino and Vered Daitch and Roni Bitterman and Hiba Zayyad and Fidi Koppel and Inbar Levi and Tanya Babich and Lena E. Friberg and Johan W Mouton and Ursula Theuretzbacher and Leonard Leibovici},
  journal={The Lancet. Infectious diseases},
  year={2018},
  volume={18 4},
  pages={391-400}
}
BACKGROUND Colistin-carbapenem combinations are synergistic in vitro against carbapenem-resistant Gram-negative bacteria. We aimed to test whether combination therapy improves clinical outcomes for adults with infections caused by carbapenem-resistant or carbapenemase-producing Gram-negative bacteria. METHODS A randomised controlled superiority trial was done in six hospitals in Israel, Greece, and Italy. We included adults with bacteraemia, ventilator-associated pneumonia, hospital-acquired… CONTINUE READING